Malaria, caused by Plasmodium parasites transmitted through Anopheles mosquitoes, has plagued humanity for millennia. According to the World Health Organization (WHO), there were an estimated 249 million cases of malaria worldwide in 2022, resulting in 608,000 deaths, primarily among children under five in sub-Saharan Africa.
Recent advances include the rollout of the RTS,S/AS01 (Mosquirix) vaccine, recommended by the WHO for children in high-risk areas. As of 2026, pilot programs in Ghana, Kenya, and Malawi have shown a 30% reduction in severe malaria cases. Additionally, the R21/Matrix-M vaccine, approved in 2023, is being deployed in several African countries with a target of 100 million doses annually.
Insecticide resistance remains a critical challenge. The WHO reports that resistance to pyrethroids, the most common class of insecticides used in bed nets, has been detected in 78 countries. New-generation nets treated with piperonyl butoxide (PBO) have been shown to reduce malaria incidence by 20-30% in areas with high resistance.
Artemisinin-based combination therapies (ACTs) remain the frontline treatment, but partial resistance to artemisinin has emerged in Southeast Asia and parts of Africa. The WHO recommends close monitoring and the development of new antimalarial drugs.
Global funding for malaria control reached $4.1 billion in 2022, short of the $7.8 billion target. The WHO's Global Technical Strategy aims for a 90% reduction in malaria incidence and mortality by 2030, but progress has stalled in recent years due to climate change, conflict, and the COVID-19 pandemic.
